Executive Summary: A New Frontier in Structural Heart Care
In a significant development for cardiovascular medicine, Abbott has unveiled compelling one-year clinical data for its next-generation Amulet 360 left atrial appendage (LAA) occluder. The results, presented at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) conference in California and simultaneously published in JACC: Cardiovascular Interventions, indicate that the device achieves high rates of complete LAA closure.
For patients suffering from non-valvular atrial fibrillation (AFib)—a condition that significantly elevates the risk of stroke—the Amulet 360 offers a promising alternative to long-term oral anticoagulation. As the global medical community continues to refine strategies for stroke prevention, the success of the VERITAS trial positions Abbott as a formidable challenger in a market currently dominated by established players like Boston Scientific.
The Clinical Necessity: Understanding the LAA’s Role in Stroke
Atrial fibrillation is characterized by an irregular and often rapid heart rate that can cause poor blood flow. In patients without heart valve issues, research has consistently identified the left atrial appendage (LAA)—a small, thumb-shaped sac in the top-left chamber of the heart—as the primary reservoir for blood clots. When these clots escape the LAA and travel to the brain, they trigger an ischemic stroke.
For many patients, the standard of care is long-term blood-thinning medication (anticoagulants). However, these medications carry significant risks, including spontaneous bleeding, which makes them unsuitable for a substantial portion of the AFib population. LAA closure devices, such as the Amulet 360, provide a mechanical, durable solution by sealing off the appendage, effectively preventing clot formation and migration without the need for lifelong pharmaceutical intervention.
Chronology: The Road to the VERITAS Readout
The journey of the Amulet 360 represents a methodical advancement in structural heart engineering.
- August 2026: Abbott achieves a major regulatory milestone by securing the CE mark in Europe for the Amulet 360, signaling its readiness for clinical adoption in the European market.
- October 31 – November 3, 2026: The medical community convenes for the TCT conference in California. During a high-profile, late-breaking session, researchers present the one-year primary results from the pivotal VERITAS (NCT06707688) clinical trial.
- Current Status: While the device is now available in Europe, it remains pending US Food and Drug Administration (FDA) clearance, leaving American cardiologists and patients awaiting the next phase of its global rollout.
Supporting Data: The VERITAS Trial Highlights
The VERITAS trial was designed to evaluate the safety and efficacy of the Amulet 360 in a real-world clinical setting. The one-year data provided a robust validation of the device’s design, focusing on closure success and patient safety profiles.
Key Performance Metrics:
- Closure Efficacy: The study reported complete closure of the LAA in 96.3% of participants. This high success rate is critical, as any residual flow around the device can still pose a risk for clot formation.
- Ischemic Stroke Prevention: Over 98% of patients remained free from ischemic stroke or complications resulting from blood clots throughout the 12-month follow-up period.
- Safety and Mortality: The safety profile was equally impressive. More than 99% of patients were free from pericardial effusion (a buildup of fluid in the sac surrounding the heart, which is a known procedural risk). Furthermore, 98% of patients were free from cardiovascular-related mortality at the one-year mark.
The device itself, a dual-seal mechanism composed of two connected nitinol metal mesh components, is designed to be softer and more conformable than its predecessor, the Amplatzer occluder. This flexibility allows for a better fit across a wider variety of LAA anatomies, which vary significantly from patient to patient.
Official Perspectives: Industry and Clinical Leadership
The implications of the VERITAS data have been met with optimism by both corporate leadership and the physicians responsible for patient outcomes.
Dr. Christopher Piorkowski, Chief Medical Officer for Abbott’s Electrophysiology Business:
"Amulet 360 was designed with enhanced conformability and sealing features intended to support durable closure across a wider range of anatomies. The one-year VERITAS results reinforce the potential of these next-generation enhancements to expand patient choice and help physicians confidently offer left atrial appendage closure to patients at the right time in their care journey."
Dr. DJ Lakkireddy, Executive Medical Director of the Kansas City Heart Rhythm Institute and Lead Author of the JACC publication:
"The VERITAS trial results are highly encouraging, demonstrating high rates of complete closure sustained through 12 months. These findings reinforce the potential of the Amulet 360 technology to provide physicians with an effective treatment option as we continue to advance strategies for stroke risk reduction in this patient population."
Implications: Market Dynamics and the Future of Stroke Care
The Competitive Landscape
The LAA closure market is currently one of the most lucrative and competitive segments in the medical device industry. According to data from GlobalData, the market is expanding at a compound annual growth rate (CAGR) of 8.5%, with projections suggesting a total valuation of nearly $6 billion by 2035—more than double its 2025 value.
Currently, Boston Scientific holds a commanding lead with its Watchman device. As of 2025, Boston Scientific occupied roughly 80% of the US market. Abbott, while currently holding an 11.7% share, is clearly looking to erode that dominance. With the introduction of the Amulet 360, Abbott is betting on superior conformability and a more sophisticated sealing mechanism to capture a larger share of the market, particularly among patients whose anatomical variations make traditional occluders difficult to deploy.
Clinical Impact
The shift toward LAA closure as a primary stroke prevention strategy represents a broader movement in medicine toward "structural solutions" for chronic conditions. By shifting the burden of care from the patient (who must remember to take blood thinners daily) to a one-time surgical procedure, providers can eliminate the risks of medication non-compliance and drug-related bleeding complications.
As the Amulet 360 moves through the regulatory pipeline in the United States, its performance in the VERITAS trial will serve as a primary pillar of Abbott’s argument for FDA approval. If approved, the device will likely become a centerpiece of electrophysiology and interventional cardiology departments, offering a more nuanced, "precision medicine" approach to LAA closure.
A Look Ahead
The success of the Amulet 360 is not merely a corporate win for Abbott; it is a clinical milestone that expands the toolset for cardiologists. With high closure rates and a low incidence of procedural complications, the Amulet 360 is poised to set a new standard for durability in structural heart care.
However, the ultimate test will be its performance in broader, real-world populations beyond the controlled environment of a clinical trial. As more physicians gain experience with the device in Europe, the data gathered will further inform the clinical community about the long-term potential of nitinol-based, dual-seal technology in the fight against AFib-related stroke.
For now, the cardiology community looks to the FDA, where the decision to bring this technology to the US market will be the final hurdle in transforming how we approach one of the most significant neurological risks facing the aging global population.
About the Author
